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Abstract
The env gene of three simian immunodeficiency virus (SIV) variants developed convergent mutations during disease progression in six
rhesus macaques. The monkeys had been inoculated with supercoiled plasmids encoding infectious proviruses of SIVmac239 (a pathogenic,
wild-type strain), SIV3 (the live attenuated vaccine strain derived from SIVmac239), or SIV3 (a pathogenic progeny virus that had
evolved from SIV3). All six monkeys developed immunodeficiency and progressed to fatal disease. Although many divergent mutations
arose in env among the different hosts, three regions consistently mutated in all monkeys studied; these similar mutations developed
independently even though the animals had received only a single infectious molecular clone rather than standard viral inocula that contain
viral quasispecies. Together, these data indicate that the env genes of SIVmac239, SIV3, and SIV3, in the context of different proviral
backbones, evolve similarly in different hosts during disease progression.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The infection of rhesus macaques with simian immuno-
deficiency virus (SIV) has been used to model human im-
munodeficiency virus type 1 (HIV-1) infection in humans.
SIV is a primate lentivirus with a genomic structure that
closely resembles that of HIV-1; SIV also infects similar
target cells as HIV-1 (Letvin and King, 1990). Furthermore,
macaques infected with SIV have similar signs of disease as
HIV-1-infected humans, such as CD4 T-cell depletion,
opportunistic infections, and wasting.
Several years ago, live attenuated SIV was considered a
promising vaccine approach (Cranage et al., 1997; Daniel et
al., 1992; Marthas et al., 1990; Putkonen et al., 1995; re-
viewed by Ruprecht, 1999). One of the proposed live atten-
uated vaccine candidates was the triply deleted mutant SIV-
mac2393, abbreviated SIV3, that contains deletions in
the nef and vpr genes and in the negative regulatory element
(NRE) of the long terminal repeat (LTR) (Gibbs et al.,
1994). Initial studies of SIV3 reported 50% protection of
adult vaccinees against challenge by wild-type SIVmac251
(Wyand et al., 1996). However, a long-term follow-up study
demonstrated that monkeys vaccinated with SIV3 were
only partially protected against challenge with a pathogenic
simian–human immunodeficiency virus (SHIV), and fur-
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thermore, no protection was seen against challenge by het-
erologous pathogenic SIVsmE660 (Wyand et al., 1999).
When SIV3-vaccinated monkeys were rechallenged after
a long time interval (up to 6.8 years) with wild-type SIV-
mac251, no protection from superinfection was seen (Hof-
mann-Lehmann et al., 2003).
Concerns about the safety of the SIV3 vaccine in neo-
nates were raised when a cohort of four infant rhesus ma-
caques developed AIDS after oral inoculation with SIV3
as newborns (Baba et al., 1995). A number of macaques also
developed disease after inoculation with cell-free SIV3 as
adults (Baba et al., 1999; Hofmann-Lehmann et al., 2003).
Taken together, these data indicated that SIV3 is patho-
genic in macaques regardless of the age of vaccination.
However, compared to wild-type SIVmac239 or SIV-
mac251, viruses that express intact nef genes in vivo, dis-
ease progression due to SIV3 infection was slower (Baba
et al., 1999; Hofmann-Lehmann et al., 2003). In both of
these studies, the SIV3 vaccine strain mutated into shorter
variants as disease progressed, and the shorter variants
eventually replaced the parental strain in the diseased mon-
keys.
Previously, monkeys inoculated intramuscularly (i.m.)
with pure proviral DNA of SIVmac239 developed disease
(Liska et al., 1999). This inoculation strategy is advanta-
geous because it eliminates the need to grow virus in cell
culture prior to inoculation. Viral preparation in cell culture
leads to the selection and evolution of viral quasi-species in
vitro that increase the complexity of the inoculum. The
infectious proviral DNA approach was used to inoculate a
cohort of monkeys with pure, supercoiled plasmids of SIV.
Here we sought to examine the evolution of the entire
env coding region of SIV as the animals progressed to
disease. We show convergent evolution of SIV env in six
different monkeys independently inoculated with the pure
proviral DNA of three SIV variants of differing pathoge-
nicity: wild-type SIVmac239, parental live attenuated
SIV3, and SIV3 progeny SIV3.
Results
Viremia and disease after inoculation with pure proviral
DNA
Neonatal (n  3) and adult (n  3) rhesus macaques
were inoculated i.m. with pure proviral DNA of SIV-
mac239, SIV3, or SIV3 (Materials and Methods and
Table 1). All monkeys, except mother/infant pair 270W and
BR6, were unrelated. All six monkeys were euthanized at
varying times (ranging from 54 to 206 weeks) following
inoculation. Necropsies were performed at time of death to
examine tissues for evidence of AIDS. Four monkeys
(270W, BR6, 18581, and BR8) had absolute CD4 T-cell
counts that were less than 200 cells/l prior to euthanasia,
and all six animals developed persistently inverted CD4/
Table 1
Summary of host monkey disease status following i.m. inoculation with pure proviral DNA
Animal No. Proviral DNA
inoculated
env inoculated Clinical outcome
270W (adult) SIVmac239 SIVmac239 AIDS, with 176 CD4 T cells/l, at euthanasia at week 54. Anemia and
thrombocytopenia; lymphoplasmacytic and eosinophilic gastroenterocolitis
and mild eosinophilic bronchopneumonia noted at necropsy.
BR5 (infant) SIV3 SIVmac239a Intermittently low CD4CD29 memory T cells starting from week 34
onward and bacterial sepsis at week 117. AIDS, with two opportunistic
infections—cryptosporidiosis (multiple tissues) and Epstein Barr-like virus
(superficial epidermis). 763 CD4 T cells/l at euthanasia at week 122.
Lymphoid follicular hyperplasia/dysplasia (lymph nodes) and intranuclear
inclusion bodies (superficial epidermis) also noted at necropsy.
22183 (adult) SIV3 SIVmac239a Inverted CD4/CD8 T-cell ratios at week 81 onward. Dyspnea and 282
CD4 T cells/l noted at euthansia at week 124. Pancreatitis, myocardial
fibrosis, generalized fat necrosis, and amyloidosis (spleen, duodenum,
stomach, and kidney) noted at necropsy.
BR6 (infant) SIV3 SIV3 AIDS, with 179 CD4 T cells/l at euthanasia at week 81. Lymphoid
follicular hyperplasia (lung, ileum, spleen, bone marrow, and lymph nodes),
chronic gastritis, eosinophilic bronchitis (lung) and enterocolitis (large and
small intestine), tonsillitis, and chronic interstitial nephritis noted at
necropsy.
18581 (adult) SIV3 SIV3 AIDS, with 99 CD4 T cells/l at euthanasia at week 206. Endometriosis,
chronic nephritis, conjunctivitis, chronic gastritis, and pulmonary ascariasis;
eosinophilia with eosinophilic infiltrates in conjunctivia, trachea, and lungs at
necropsy.
BR8 (infant) SIV3 plus SIV3
(1:1 mixture)
SIVmac239a
plus SIV3
(1:1 mixture)
AIDS, with 193 CD4 T cells/l at euthanasia at week 59.
Cryptosporidiosis (multiple tissues), pneumocystosis, emaciation, and
dehydration noted at necropsy.
a SIV3 shares the same env sequence as SIVmac239.
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CD8 T-cell ratios during disease progression. Thus, all ani-
mals developed immunodeficiency during this study (Table 1).
In addition, viral loads were measured using real-time
reverse transcriptase–polymerase chain reaction (RT–PCR)
during disease progression and at time of death (Fig. 1). The
monkey that received wild-type SIVmac239 proviral DNA
(adult 270W) was unable to clear high viral loads through-
out disease progression (Fig. 1A), with levels between 107
and 108 RNA copies/ml. Viral loads were also measured in
animals that received SIV3 (Fig. 1B). Infant BR5 main-
tained high viral loads throughout disease progression (104
and 107 RNA copies/ml). Although adult 22183 was able to
clear virus below our threshold of detection after the initial
peak of viremia, viral loads rebounded later in disease
progression to between 103 and 104 RNA copies/ml. Both
animals that received SIV3 DNA were unable to clear
viremia during disease progression, with infant BR6 and
adult 18581 maintaining levels between 104 and 106 RNA
copies/ml and 103 and 106 RNA copies/ml, respectively
(Fig. 1C). Finally, the infant that received an equimolar
mixture of SIV3 and SIV3 (BR8) had persistently high
viral loads throughout disease (Fig. 1D), with no clearing of
virus.
PCR, cloning, and sequencing
PCR with primers specific to the SIV3 env gene was
used to detect env in genomic DNA extracted from monkey
BR5s peripheral blood mononuclear cells (PBMC) at 39
weeks postinoculation (early stage disease) and 111 weeks
postinoculation (late stage disease), as well as from lymph
nodes, thymus, and spleen collected at necropsy (week 122
postinoculation). PCR was also performed on DNA ex-
tracted from the spleens of animals BR8, 270W, 18581, and
BR6 and the lymph nodes of 22183. PCR products were
cloned and sequenced as described under Materials and
Methods; five clones per sample were sequenced and com-
piled into a consensus amino acid sequence. Heterogeneity
among amino acids within a sample’s five clones is de-
scribed in Table 2.
Evolution of SIV3 Env in an infant monkey
One infant monkey, BR5, had received proviral SIV3,
a triply deleted mutant virus derived from wild-type SIV-
mac239. Potential Env amino acid sequences were aligned
to compare the early (39 weeks postinoculation) and late
(111 weeks postinoculation) Env sequences, as well as the
Env sequences from the spleen, lymph nodes, and thymus at
the time of necropsy (122 weeks) (Fig. 2). Mutations were
noted in every variable loop as well as in regions outside
variable loops. Although some mutations were unique to
one particular BR5 clone (perhaps due to conditions in that
particular organ), several shared mutations arose among the
clones. Additionally, 15 residue changes were shared with
the Env sequence of SIV3, a progeny virus that was
isolated from a different monkey independently inoculated
with SIV3 (Khimani et al., unpublished data).
Evolution of Env in five monkeys inoculated with one of
three SIV variants
To further examine the in vivo evolution of SIV env, we
compared env sequences of samples that had been collected
from six animals at necropsy. Sequences of these samples
would correspond to the virus present in the tissues at the
time of death. Three animals (270W, BR5, and 22183)
received the same SIVmac239 env, but in the context of
different proviral backbones; 270W received wild-type
SIVmac239 proviral DNA, whereas BR5 and 22183 both
received SIV3 proviral DNA. Two animals (18581 and
BR6) received SIV3 progeny proviral SIV3, with its
unique env. Finally, one animal (BR8) received an equimo-
lar mixture of SIV3 and SIV3 (and therefore both
SIVmac239 env and SIV3 env). The alignment of these
consensus sequences as well as parental SIVmac239 Env
(identical to SIV3 Env) and SIV3 Env are shown in
Fig. 3.
Fig. 1. Plasma viral loads after inoculation of proviral DNA were measured
by real-time RT–PCR. The threshold of detection (50 RNA copies/ml) is
indicated by a dotted line. Open squares indicate adults, and closed dia-
monds indicate infants. (A) Viral loads of an animal inoculated with
proviral DNA of SIVmac239. (B) Viral loads of two animals inoculated
with proviral DNA of SIV3. *Plasma samples from time of death for BR5
(week 122 postinoculation) and 22183 (week 124 postinoculation) were
unavailable. (C) Viral loads of two animals inoculated with proviral DNA
of SIV3. (D) Viral load of an animal inoculated with an equimolar (1:1)
mixture of SIV3 and SIV3 proviral DNA. aBy week 2 postinocula-
tion, SIV3 strongly predominated in this monkey over SIV3.
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Many mutations were unique to each particular animal.
However, several mutations (highlighted in Fig. 3) were
shared among three or more clones, even though all animals
were independently inoculated. Most mutational changes
were clustered in the variable loops, mainly in the V1 and
V4 loops, although several clones showed one mutation in
the V2 loop, two clones (18581 and BR6) developed a
mutation in the V3 loop, and one clone (BR5) developed
one mutation in the V5 loop. Interestingly, 21 mutations that
arose in the Env gene of the SIV3 progeny virus,
SIV3, were retained in both Envs isolated from the
animals (18581 and BR6) that received SIV3 as a pro-
viral inoculum. This included three residues in the V1 loop
and five residues in the V4 loop, including the N-linked
glycosylation site at residues 415–418. Mutations in other
variables loops that arose in SIV3 were never retained in
both progeny clones of SIV3. In the one animal (BR8)
that received an equimolar mixture of SIV3 and SIV3,
Table 2
Sequence heterogeneity among five clones
Animal source of
Env
Deviationsa from consensus sequence among five clones sequenced per sample
Frequency Mutation
270W 1 of 5 L24Q, M67V, K125Q, T181A, T181K, G201D, R293K, Y304F, M325L, N375K, N375R, D413G,
T417A, Q419*, K420*, P421*, Q422*, Q422K, E423*, R424*, R424Q, T462S, D471V, D474N,
E488K, V500L, H511D, H511G, Q564R, R574G, N633D, A685T, E755K, G837V, L845P
2 of 5 *140A, *141K, N148T, E202N, R345W, E631K, R716K, 1789T, S792L, G804R
BR5 39 weeks 1 of 5 Q85P, A140*, K141*, A153T, E182K, E218D, S219F, R345W, K351R, Q359H, K375R, W410*,
*421P, *426K, M482L, G519D, G526E, M543I, T549A, N633S, G694E, G754R, D757G, N786S,
1801M, R804G, R817M, G826R, V837A, T842A
2 of 5 K103R, P139S, *418N, *419Q, *420K, G753D
BR5 111 weeks 1 of 5 V26A, Q56H, D62G, L67M, A131T, S135T, T136V, A138T, S139T, S139B, K141*, K181R,
D201G, Y238F, S272P, D294G, Y367S, V388A, T417A, T417V, N418*, N418K, Q419*, Q419H,
K420*, *422K, *423G, *424Q, *425H, R427G, N428I, Y429T, K446R, N447T, I473V, Q477R,
Q477K, M482L, T503S, Q566K, S676D, S676N, T685A, V711I, D753G, E767Q, V834T, V837A,
A840S
2 of 5 Q24L, V32I, T137A, S150P, 1215V, N372D, *421P, *426K, S627N, G757D, H774R, I801M,
G804R, I855T
BR5 spleen 1 of 5 Q56H, W91S, R103K, T130A, A131T, T137A, A138T, S141*, S141K, S141R, V142A, V145I,
K181R, D372N, S511G, G518S, V562G, D602G, I708V, V711I, E747G, G748D, E750G, N759S,
S761F, N786S, T789A, I801M, T855I
2 of 5 I71V, K120R, S132T, T135S, P139S, A140*, D143N, S149N, S150P, K310R, R446K, R513K,
R631K, D633N, M713L, R746K, G756E, G757D, S785N, R817M, V837A, A840S
BR5 lymph nodes 1 of 5 L42D, N48I, N79S, S132T, S135T, P137V, P137A, P137T, D143N, D143M, R296G, K418N,
P421*, K422*, *423G, *424Q, *425H, *426K, Q477K, Q477H, R513K, G518S, M713L, P741Q,
E747G, S785N, T789A, G804T, T808I, Q824H, H831Q, T855I, T855A
2 of 5 R103K, K120R, *141K, *142V, N149S, A153T, K181R, V215I, K310R, K446R, S511G, V711I,
E750G, G756D, G757D, M801I
BR5 thymus 1 of 5 Q24L, 132V, D50A, W52C, Q56H, A131T, S132P, T135S, *140A, D143E, D143N, P150S,
A153T, Q164H, K293R, R327G, E349N, K358M, D372N, P421H, K422*, R427*, N428*,
K446R, D456V, K477Q, I482M, S511G, K513R, S518G, I543M, K592R, Y611C, K635E,
E641G, S679G, I711V, R716K, Q719R, G756D, D757G, D767Q, G826R, R860G
2 of 5 R19G, A68V, R120K, K141*
22183 1 of 5 120V, Q24L, V32D, V71A, S139L, C151Y, C261R, K349E, D372N, A374D, R375K, N377S,
E423*, Q424*, Y425*, K426*, P431S, I437V, T626A, L628P, D633N, D757G, L771F, R868K,
R871I
2 of 5 R141K, N199S, G201D, K254N, M309I, L655P
BR6 1 of 5 L9R, A38V, L126P, N127T, Q129S, T130I, A131T, P132S, T134A, K181R, G201D, I216M,
C220G, P236T, G237C, S256A, R281I, R285K, H304R, R312I, S318T, V322I, R338W, R375K,
L378S, S626T, P728H, S732F, K749R, V815I, V834A, L845F, I855T, P868R
2 of 5 W52L, H291P, L320V
18581 1 of 5 N6S, W21S, K120R, I127M, A131T, S135P, T137P, P150S, C168W, E185K, D201G, T214S,
K254N, R293K, R293G, N316K, K363Q, R375K, V411I, E412K, H442L, K446M, L450F,
S521T, T549P, N627S, R631E, E633N, E633K, F646L, E656G, E668K, V699I, R716K, M743L,
G756S, G756D, E767A, N786S, T789A, I808T, R811K, S840A, A841T, T844A
2 of 5 A110T, K115R, T139A, N199S, I480V, N511S, G518S, T626A, A836T
BR8 1 of 5 R36M, A38T, L42P, W52L, L58P, S97P, T110A, T134K, T137P, K176T, R312I, V322L, T626A,
D633N, P655L, D757G
2 of 5 T136A, A140E, K141E, V142E
* Indicates a deletion in the sequence at this residue.
a Deviations are notated as the consensus sequence amino acid and its numerical position, followed by the amino acid deviation.
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mutations arose in the V4 loop, but not in the V1 loop, as
had occurred for all other clones. This could be because this
animal lived only for 59 weeks postinoculation.
Among the convergent mutations noted in the Fig. 3
alignment is a potential novel N-linked glycosylation site at
amino acids 415–418 that arose in every single progeny
clone (including SIV3). In the sequences isolated from
animals that received SIV3, which already contained the
glycosylation site, the site was retained. N-linked glycosyl-
ation of Env in this region has been shown to reduce
neutralizing antibody recognition of SIVmac239 (Kinsey et
al., 1996).
Phylogenetic analysis of Env clones
To further determine the relationship between all Env
clones presented in this article, a phylogenetic tree was
constructed (Fig. 4) with parental SIVmac239 Env as the
outgroup. As shown by the small branch lengths, the se-
quences are all very closely related. However, clones am-
plified from SIV3-inoculated animals BR6 and 18581
were closely related to SIV3 and each other, whereas
clones amplified from SIV3-inoculated animals were not
as closely related to each other. These data suggest that
SIV3 clones did not evolve as much as SIV3 clones,
perhaps because SIV3 was a passaged virus that had
already evolved to be better adapted to the host environ-
ment, possibly by eluding host immune responses.
Convergent mutations of SIV Env in six independently
inoculated animals
Table 3 shows amino acids that evolved from SIV3
Env in two or more clones. In this table, SIV3 is also
included as a progeny clone of SIV3. In all, 44 amino
acids changed from SIV3 Env in two or more clones, and
eight amino acids mutated in six or more clones. Of these
eight, one resulted in a potential novel N-linked glycosyla-
tion site (415 NTAN 4183 415 NTTN/K 418). In addition
to the striking appearance of this novel glycosylation site in
every independently inoculated animal, two other regions
(the V1 and V4 loops) exhibited high degrees of mutational
change (Table 4). Although in each case the clones devel-
oped unique mutations, these three regions never remained
intact in any clone (except BR8 who did not display any
mutations in the V1 loop).
Discussion
Here, we demonstrated convergent evolution of SIV env
in monkeys that had been inoculated with cloned proviral
Fig. 2. Predicted amino acid sequence changes of SIV Env amplified from infant BR5. Five clones were sequenced per sample; consensus amino acid
sequences are shown. Sequence heterogeneity among the five clones is listed in Table 2. BR5 Env sequences are aligned with the parental SIVmac239 Env
sequence (mac239 Env), which has the same sequence as SIV3 Env (d3 Env); sequences were also aligned with the independent molecularly cloned
infectious progeny virus SIV3 (d3 Env). (), conserved residues; (*), deleted residues; box at residues 415–418, potential novel N-linked glycosylation
site; arrow between residues 525 and 526, putative proteolytic cleavage site; bracketed residues, variable loops V1–V5. Highlighted residues indicate
mutations in BR5 sequences that are shared with progeny SIV3. Env sequences were amplified early (week 39 postinoculation) and late (week 111
postinoculation) during disease progression and from necropsy samples spleen, lymph nodes, and thymus (week 122 postinoculation).
Fig. 3. Predicted amino acid sequence changes in SIV env isolated from six
animals at necropsy. Five clones were sequenced per sample; consensus amino
acid sequences are shown. Sequence heterogeneity among the five clones is
listed in Table 2. The times at which the samples were collected postinocula-
tion are indicated in parentheses after each sample. Three animals (270W,
BR5, and 22183) received a SIVmac239 env but in the context of different
proviral DNA backbones: 270W in SIVmac239 and BR5 and 22183 in
SIV3. Two animals (BR6 and 18581) received pathogenic progeny virus
SIV3 proviral DNA. One animal (BR8) received an equimolar mixture of
proviral DNA encoding SIV3 and SIV3, therefore receiving an equimo-
lar mixture of SIVmac239 and SIV3 envs. These sequences are aligned with
parental SIVmac239 Env (mac239 Env), which has the same env as SIV3
(d3). Additionally, SIV3 Env (d3 Env) precedes the monkeys that re-
ceived SIV3 proviral DNA. Highlighted residues indicate mutations that
occurred in three or more sequences, including SIV3, as it was a progeny
virus of SIV3. Symbols are as described in the FIG. 2 legend. The triangle
between amino acids 137 and 138 of BR6 indicates an insertion of the amino
acids STP in this consensus sequence.
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DNA of one of three viral variants with different pathoge-
nicity. Since the monkeys received a single molecular pro-
viral clone, no viral quasi-species were present in the inoc-
ula. In all, six unrelated monkeys (except for mother–infant
pair 270W and BR6) were infected with SIV. Although each
env clone developed unique mutations, three important con-
vergent mutations arose in all independently inoculated an-
imals: variations in the V1 and V4 loops and a potential
novel N-linked glycosylation site in the V4 loop. Several
convergent point mutations were documented as well.
The present study highlights eight Env point mutations
that arose in most (5/6 or 6/6) infected animals as well as
other mutations that did not occur as frequently. Most of
these mutations occurred in previously documented immu-
noreactive regions. According to a study by Miller et al.
(1992) that identified antibody epitopes on SIVmac251 Env,
residues V67, N372, K375, D511, and R751 occurred either
inside or immediately outside (within one residue) a SIV-
mac251 antibody epitope that could be shared with SIV-
mac239 Env. Cole et al. (2001) identified antibody epitopes
of the Env glycoproteins of SIVmac239. Residue A141
occurred within one of the identified epitopes. Residue
A417 occurs within a neutralizing antibody epitope of SIV-
mac239 (Torres et al., 1993). Furthermore, residue D511 is
immediately outside (within one residue) a region that has
been implicated as a CTL epitope region (Yasutomi et al.,
1995). Although we know of no studies that have placed
residue V837 within an antibody or CTL epitope, the pos-
sibility cannot be excluded; however, the position V837
could be part of a conformational Env epitope. Conforma-
tional changes and alteration of the glycosylation profile
have been shown to play an important role in affecting
antibody binding (Javaherian et al., 1994) but could also
affect CTL and coreceptor binding as well.
In addition to the many frequently occurring point mu-
tations documented in this study, there were also three areas
where mutations were focused heavily. These included the
V1 and V4 loops as well as a region encoding a potential
novel N-linked glycosylation site in the V4 loop.
In our animals, mutations in the V1 loop were the most
variable, with deletions, insertions, and substitutions. SIV
Env sequenced from the PBMC DNA of BR5 at early-stage
disease and the spleen DNA of BR5, 22183, and BR6 had
substitution mutations; SIV Env sequenced from BR6
spleen also had a three-amino-acid insertion at this site; and
SIV Env sequenced from BR5 lymph nodes, BR5 thymus,
270W spleen, and 22183 lymph nodes had a one- or two-
amino-acid deletion at this site. An independent in vivo
study (Burns and Desrosiers, 1991) showed sequence vari-
ation in the V1 loop located in the vicinity of amino acid
140. These studies corroborate the importance of these mu-
tations in env evolution.
Mutations in the V4 loop consisted of point mutations
and deletions, occuring mainly between amino acids 420
and 427. Although deletion mutations in the V4 loop did not
occur in all env clones, they were observed in 7 of 10
clones: SIV Env from BR5 early-stage, BR5 late stage, BR5
spleen, BR5 lymph nodes, BR5 thymus, 18581 spleen, and
BR6 spleen. Among animals that harbored viruses without
this deletion—BR8, 270W, and 22183—two exhibited a
very fast disease course (BR8 and 270W) and 22183 exhib-
ited lower viral loads than other animals throughout its
disease course. BR8 and 270W died at 59 and 54 weeks
postinoculation, respectively. Since these monkeys died
early relative to the other monkeys in the study, perhaps the
time course of disease was too short to develop the V4
deletion. However, these three monkeys still developed sub-
stitution mutations in this region, ensuring that the 423–426
SIV3 sequence never remained intact in any animal stud-
ied.
The appearance of the V4 deletion was also documented
in two in vivo studies of HIV env evolution (Beaumont et
al., 2001; Hofmann-Lehmann et al., 2002). In a study of the
disease course of a laboratory worker accidentally infected
with neutralizing antibody-sensitive HIV-IIIB that reverted
to a neutralization-resistant strain as disease progressed,
sequencing of the entire env coding region showed that a
four-amino-acid deletion occurred in the V4 loop, the same
location as that in the present study (Beaumont et al., 2001).
Another study (Hofmann-Lehmann et al., 2002) examined a
Fig. 4. Phylogenetic relationship of SIV Env in progeny viruses of SIV3. Phylogenetic analysis was carried out by initial amino acid sequence alignment
of Env using the Gonnet 30 Protein Matrix in the ClustalX alignment program. The tree was constructed with the PAUP software in the Phylip program,
version 3.6, using the exhaustive tree search. We used the distance parameter and sampled 100 trees. Numbers on the branches represent branch lengths.
SIVmac239 Env (which is the same as SIV3 Env) was entered as the outgroup to generate a rooted tree.
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monkey infected with SHIV containing an SIV backbone
with HIV-IIIB env. Sequences amplified from this monkey
had developed deletions in the V4 region of Env as well.
The V4 deletions documented in the present study occurred
in a known neutralizing antibody epitope of SIVmac239
(Choi et al., 1994) and SIVmac142 (Torres et al., 1993). The
presence of a neutralizing antibody epitope in the SIV V4
region suggests the selection of neutralization escape vari-
ants as a reason for the appearance of this mutation.
Another striking mutational change was the appearance
of the NTTN/NTTK potential novel N-linked glycosylation
site in the V4 loop (amino acids 415–418 in SIVmac239).
Every clone in this study developed the NTTN or NTTK
glycosylation site, except for the early-stage Env sequence
amplified from BR5. In another study that followed mon-
keys inoculated with SIVmac239, the env genes were
cloned and sequenced from different time points (Burns and
Desrosiers, 1991). Interestingly, the NTTN/NTTK N-linked
glycosylation site was not present in early-stage disease
samples; however, it was present in every sample obtained
in late stages of infection or at necropsy. Another study
showed that cloned env isolated from monkeys that had
been inoculated with SIVmac239 displayed the NTTN/
NTTK potential N-linked glycosylation site and that this
change resulted in altered neutralizing Ab recognition (Kin-
sey et al., 1996). In total, this N-linked glycosylation site
arose in at least 15 independently inoculated animals from
three different studies (Burns and Desrosiers, 1991; Kinsey
et al., 1996; present study). Therefore, the generation of
novel N-linked glycosylation sites in this region could affect
neutralizing antibody recognition, thus leading to selection
of neutralization escape variants.
In sum, SIV env develops similar mutations during dis-
ease progression in different hosts inoculated with the pure,
cloned proviral DNA of one of three different proviral
backbones. Although mutations among different animals
did vary considerably, three important convergent muta-
tions arose in all independently inoculated animals: varia-
tions in the V1 loop, a deletion and substitution site in the
V4 loop, and a potential novel N-linked glycosylation site in
the V4 loop. Since these mutations arose consistently
among independently inoculated, unrelated hosts and in
other independent studies, they probably provide SIV with
enhanced replication fitness regardless of host genetic back-
grounds. Additional studies showed that the V4 deletion site
is located in an important neutralizing antibody epitope.
However, other factors that enhance viral replication capac-
ity, such as CTL escape, intrinsic mechanisms that enhance
viral replication competence, and broader target cell tro-
pism, could be involved as well. Increased replication ca-
pacity, in turn, would then lead to faster disease progression.
Our study, which relied on cloned infectious proviruses,
conclusively showed that the SIV env gene evolves along
similar paths in different individual hosts, as the convergent
mutations were generated de novo rather than selected from
viral quasispecies that may arise during the propogation of
a cell-free virus stock.
Table 3
Similar SIV Env evolutiona in six monkeys independently inoculated
with one of three SIV variants
SIV3 Env
amino acid
changes
Clones with this change
I20T BR6, 18581, BR8, SIV3
L24Q BR5, 22183
G62D BR5, BR6
V67Lb 270W (M)c, BR5, 22183 (M), BR6, 18581, BR8,
SIV3
R120K BR5, 18581
S126L BR6, SIV3
T129S 18581, BR6 (Q), SIV3(P)
S135T BR5, 22183 (*)
A138* BR6, 18581, SIV3
S139T BR5 (P), BR6, 18581, SIV3
K141S 270W(*), BR5, 22183 (R), BR6, 18581, SIV3
N199S BR6, BR8, SIV3
G201D BR5, 18581
K264N BR6, SIV3
R293K 22183, BR8
W345R 270W, BR5
K351Q BR6, 18581, SIV3
N372D BR5, 22183, BR6, 18581, BR8, SIV3
D374A 22183, BR6, 18581, BR8, SIV3
K375R 270W (N), 22183, BR6, 18581, BR8, SIV3
N405D BR5, 18581, BR6, SIV3
A417T 270W, BR5 (K), 22183, BR6, 18581 (K), BR8,
SIV3
P421* BR6, 18581, SIV3
K422* 270W (Q), BR6, 18581, SIV3
E423* BR5, BR6, 18581, SIV3
Q424* 270W (R), BR5, 18581
H425Y BR5 (*), 22183, 18581 (*), BR8
E485D BR6, 18581, SIV3
L499V BR6, 18581, SIV3
D511N 270W (H), BR5 (S), 22183, BR6 (E), 18581,
BR8, SIV3
A626T 22183, BR6 (S), 18581, BR8
K631R 270W (E), BR5, 18581, SIV3
N633D BR5, 22183, 18581 (E), BR8, SIV3
K716R 270W, BR5, BR6, 18581, SIV3
R751G 270W, BR5, 22183, BR6, 18581, BR8, SIV3
G757D 22183, BR8
F771L 22183, BR8
R778H BR6, 18581, SIV3
T789I 270W, 18581
L802F BR5, BR6, 18581, SIV3
R804G 270W, BR5, 18581
V837A 270W (G), 22183, BR6, 18581, BR8, SIV3
T855I BR6, SIV3
* Indicates a deletion in the sequence at this residue.
a Mutations that occurred in two or more clones are indicated.
b Lines in bold writing indicate that mutation occurred in five or more
animals.
c Mutations that occurred at this amino acid but differ from what is
indicated in the left column are indicated with parentheses.
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Materials and methods
Animal care and selection.
Animal experiments were approved by the Animal
Care and Use Committees at Bioqual, Inc. (Rockville,
MD), Emory University (Yerkes National Primate Re-
search Center, Atlanta, GA), and the Dana-Farber Cancer
Institute. The facilities at Bioqual, Inc. and Yerkes are
accredited by the Association for Assessment and Ac-
creditation of Laboratory Animal Care International
(AAALAC). Procedures complied with the Principles
for Use of Animals, the Guide for the Care and Use
of Laboratory Animals, the provisions of the Animal
Welfare Act, and other applicable laws and regulations.
Before procedures that required removal of animals
from cages, animals were anesthetized with ketamine;
restraining devices were unnecessary during these pro-
cedures. Animals with advanced disease were eutha-
nized with a lethal dose of sodium pentobarbital intra-
venously (i.v.). All juvenile/adult monkeys selected for
this study tested negative by serology and PCR for simian
T-cell leukemia virus type I (STLV-I) (Liska et al.,
1997a) and simian retrovirus type D (SRV/D) (Liska
et al., 1997b).
DNA inoculations of monkeys
Adult and neonatal macaques each were inoculated i.m.
with 500 g of supercoiled SIVmac239, SIV3, or
SIV3 (Khimani et al., unpublished data) proviral plas-
mid DNA. Inoculations were performed as described by
Liska et al. (1999). Infant BR8 received an equimolar mix-
ture of SIV3 and SIV3 (500 g total DNA).
Real-time RT–PCR assays
The QiaAmp Viral RNA Mini Kit (Qiagen, Valencia,
CA) was used to extract viral RNA from animal plasma.
Real-time RT–PCR assays were performed as described
(Hofmann-Lehmann, et al., 2000). Our threshold for detec-
tion was 50 RNA copies/ml.
Genomic DNA extraction
PBMC and the necropsy tissues were kept at 70°C
until DNA extraction. High-molecular-weight genomic
DNA was isolated using DNAzol (Molecular Research Cen-
ter, Cincinnati, OH) as described (Liska and Ruprecht,
1999).
PCR
PCR was performed on monkey genomic DNA. Prim-
ers env-1 (5-TTTTTGGATCCATGGGATGTCTTGG-
GAATCAGCTGCTTATC-3) (corresponding to nucleo-
tides 6563 to 6592 in the proviral genome of SIV3) and
env-2 (5-TTTTTCTCGAGTCACAAGAGAGTGAGC-
TCAAGCCCTTGTGCT-3) (nucleotides 9173 to 9202),
containing a BamHI and XhoI restriction site (under-
lined), respectively, were used to generate full-length env
DNA, using a mixture of Taq and Proofreading polymer-
ase (Expand Long Template PCR, Roche, Mannheim,
Germany). Reactions were performed with 1.75 mM of
MgCl2, 350 M of dNTPs, and 300 nM of primers.
Thermocycling was performed on the Perkin–Elmer Ge-
neAmp PCR System 9600 with the following conditions:
2 min at 94°C once, 10 s at 94°C, 30 s at 57°C, and 2 min
at 68°C repeated 8X and then 10 s at 94°C, 30 s at 65°C,
Table 4
Four regions of convergent mutation of SIV Env
DNA inoculum Animal sample
(time of collection)
Regions of change from SIV3 Env
V1 loop 415–418
glycosylation
V4 loop
SIVmac239 270W spleen (week 54) A140*, K141* NTAN 3 NTTN K423Q, Q425R
SIV3 BR5 spleen (week 122) R120K, S135T, S139P, K141S NTAN 3 NTTK N405D, E423*, Q424*,
K425*, H426*
22183 lymph nodes
(week 124)
S135*, T136*, K141R NTAN 3 NTTN H425Y
SIV3 BR6 spleen (week 81) S126L, I127N, T129Q, S132P,
insertion of STP between aa
137 and 138, A138*, S139T,
K141S
NTAN 3 NITN N405D, P421*, K422*, E423*
18581 spleen (week 206) R120K, T128A, T129S,
S132P, S135P, A138*, S139T,
K141S
NTAN 3 NTTKa N405D, N418*, Q419*,
K420*, P421*, K422*, E423*,
Q424*, K425*
SIV3/SIV3
(1:1 ratio)
BR8 spleen (week 59) none NTAN 3 NTTN H425Y
* Indicates a deletion in the sequence at this residue. a This glycosylation site was generated due to a deletion.
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and 2 min at 68°C repeated 30X, followed by a 7-min
extension at 68°C. As positive control, a plasmid con-
taining the env gene from SIV3 was used in place of
genomic DNA, and as negative control, water only was
used. The presence of PCR product was detected using a
0.7% agarose gel (not shown).
Cloning and sequencing of env
PCR products were cloned directly into the PCR4-TOPO
vector (containing 2 EcoRI sites flanking the PCR product),
using the TOPO TA Cloning Kit (Invitrogen Life Technol-
ogies, Carlsbad, CA). After transformation of Escherichia
coli, five white colonies per plate were selected, purified
using the Qiagen Miniprep Kit (Qiagen), and cut with
EcoRI to verify the presence of a PCR insert. Plasmids with
the correct insert were screened for the correct initial 500-bp
sequence with the M13F primer (Invitrogen). Env se-
quences that aligned correctly with SIV3 env were se-
lected for complete sequencing. Primers used to obtain
full-length env sequences (listed in Table 5) generated
100-bp overlapping regions to facilitate the correct se-
quence order.
Sequence analysis
Sequences were aligned using DNAsis. The env DNA
sequences from 5 colonies per clone were translated into
protein sequences; a consensus amino acid sequence was
compiled for each clone. The Expasy Scan Prosite Web site
(http://ca.expasy.org/tools/scanprosite, 12/15/01) was used
to determine the location of N-linked glycosylation sites in
the consensus amino acid sequences.
Nucleotide sequence accession numbers
Nucleotide sequences of the env variants in Figs. 2 and 3
are available from GenBank (Accession numbers AY290707
through AY290716).
Construction of a phylogenetic tree
Initial sequence alignments were performed using the
ClustalX Program (Israeli National Node Protein Struc-
ture Server, Weizmann Institute of Science, Rehovot,
Israel). The phylogenetic bootstrap tree was constructed
using the PAUP software in the Phylip program, version
3.6 (Genetics Computer Group, Madison, WI), using the
exhaustive tree search, which samples 100 trees prior to
generating the best tree. We used the distance parameter
to draw the tree. The SIVmac239 sequence was consid-
ered the outgroup of the tree for rooting purposes.
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